ERBB2 and breast cancer: A 2016 consensus statement from the Society of Surgical Oncology20 declared SNLB avoidable in clinically node-negative women aged ≥70 years with early-stage hormone receptor-positive, HER2-negative invasive BC; however, our experience shows that current clinical practice still diverges from these recommendations.37 In our population, 49.2% of cN0 patients underwent SLNB (the majority were performed before 2016), while all 12 cN+ patients underwent ALND.